ClinicalTrials.gg
RecruitingNCT07608848DOTA-STR-17126Updated Jun 10, 2026

First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer

An Early Phase 1 interventional study of [177Lu]Lu-DOTA-STR-17126 and [68Ga]Ga-DOTA-STR-17126 in Metastatic Breast Cancer, Metastatic Prostate Cancer and GRPR-Targeted Molecular Imaging, sponsored by Integrated Haematology and Oncology Network. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Integrated Haematology and Oncology Network · Early Phase 1, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 403 studies in Breast Neoplasms with a site in Australia — 85 open to participants now, 156 under way, 61 of them phase 3. Breast Neoplasms · Australia.

Planned enrollment
357th of 381
20 · median 252
Started
2026
with 16 others
Phase 1
72 of 403
23 open now
Primary completion
2028-05
later than 108 of 155 live
Registered
395th of 403
by date

Among the 403 studies in Breast Neoplasms with a site in Australia, this one is the 357th largest by planned enrollment of the 381 interventional ones that give a count, is one of 17 that started in 2026, is one of 72 in phase 1, reaches primary completion later than 108 of the 155 other live ones, and was the 395th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

85 of the 403 studies in Breast Neoplasms with a site in Australia are open now. Recruiting first, the newest first:

79 more — sign in →

All 85 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 403 studies in Breast Neoplasms with a site in Australia, or all of them as a file.
02

Study summary

This is an open-label, first-in-human, exploratory Phase 0 study evaluating the safety and diagnostic imaging performance of the DOTA-STR-17126 theranostic pair in patients with advanced or metastatic breast or prostate cancer. The study investigates [68Ga]Ga-DOTA-STR-17126 for PET imaging and, in patients with positive GRPR uptake, a low dose of [177Lu]Lu-DOTA-STR-17126 for SPECT imaging and dosimetry.

The primary objective is to assess safety and tolerability. Secondary objectives include evaluation of imaging quality, biodistribution, pharmacokinetics, and radiation dosimetry. Exploratory objectives assess correlations between GRPR expression in tumour tissue and imaging uptake.

The study is conducted at a single centre in Australia, with 12 evaluable participants (up to 20 enrolled), and supports the development of a GRPR-targeted theranostic approach for personalised cancer management.

Read the detailed description

This study is an open-label, first-in-human, exploratory Phase 0 clinical trial conducted at a single centre in Australia to characterise the safety profile, imaging performance, biodistribution, pharmacokinetics, and radiation dosimetry of the DOTA-STR-17126 theranostic pair in patients with advanced malignancy. The investigational approach uses a stepwise theranostic design in which all enrolled participants receive a single intravenous bolus administration of the GRPR-targeted PET radiopharmaceutical [68Ga]Ga-DOTA-STR-17126, followed by serial whole-body PET/CT imaging to evaluate tumour uptake and normal organ distribution. Participants demonstrating sufficient GRPR-positive tumour uptake on PET imaging may subsequently receive a single low-dose, slow intravenous infusion of [177Lu]Lu-DOTA-STR-17126, with serial planar and SPECT/CT imaging performed over several days to assess biodistribution and enable organ and tumour dosimetry calculations. Blood and urine samples are collected at predefined time points to support pharmacokinetic and radiation dosimetry analyses, alongside intensive clinical and laboratory safety monitoring. The study is exploratory in nature and is designed to optimise imaging protocols, generate human dosimetry data, and establish an initial safety and tolerability profile for this novel GRPR antagonist-based theranostic platform, thereby informing the design and dose selection for subsequent phase I/II clinical development.

03

Conditions studied

  • Metastatic Breast Cancer
  • Metastatic Prostate Cancer
  • GRPR-Targeted Molecular Imaging
  • Theranostic Radiopharmaceuticals
  • Cancer
  • Active Cancer
  • Theranostic
  • Radiopharmaceutical
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Inclusion criteria refer to the enrolment of participants for the PET/CT and SPECT/CT imaging with the radioligands; PET imaging tracer [68Ga]Ga-DOTA-STR-17126 and with the SPECT imaging tracer [177Lu]Lu-DOTA-STR-17126. Participants must meet all of the following inclusion criteria to be eligible for enrolment.

  1. Ability to understand and willingness to provide
  2. Adults ≥ 18 years of age
  3. Must have the following or cytologically confirmed diagnosis of advanced or i. breast cancer ii. prostate cancer
  4. (ECOG) Performance Status 0-1
  5. Participant must have clinical or radiological documented tumour progression as established by the Investigator within 30 days of signing consent for the study
  6. Participants who have exhausted standard-of-care systemic therapies in their metastatic setting. At least one detectable by conventional imaging tumour lesion with any diameter of ≥ 1 cm in size
  7. Participants must have adequate organ and bone marrow function, defined as follows:

    i. (ANC) ≥ 1000 cells/mm3 ii. count ≥ 100,000/mm3 iii. ≥ 9.0 g/dL iv. , ALT, alkaline phosphatase ≤ 3 times (ULN) if there is no evidence of liver metastases or ≤5 ULN in the presence of liver metastases v. Total ≤ 2 times upper limit of normal (ULN) vi. Creatinine ≤ 2 times ULN and (CrCL) ≥ 60mL/min using the Cockcroft Gault equation (Appendix 2)

  8. Able to remain still for up to 60 minutes per scan
  9. Any other condition which, in the opinion of the Investigator, would preclude participation in this study Optional: Participants that have available (at least 15 consecutive, unstained, formalin-fixed, paraffin embedded (FFPE) slides or 1 FFPE block), or a fresh tumour biopsy sample that opt to provide samples will be used for GRPR analysis (histology staining or RNA measurements). Participants without any archival tissue or fresh biopsy sample, or who refuse to provide archival tissue are still eligible for the study.

Exclusion criteria

Exclusion Criteria:

Participants must not be enrolled into the trial if one or more of the following criteria are met. Participants must NOT meet any of the following Exclusion criteria to be eligible for enrolment:

  1. Known to the medicinal products (DOTA-STR-17126) or any of the .
  2. Participants with Class 3 or 4 (NYHA) Congestive Heart Failure.
  3. Average (using the Fridericia correction calculation) > 470 msec for females and QTcF >450 msec for males on screening or history of congenital long QT syndrome.
  4. bleeding within two weeks prior to trial entry (i.e., gastrointestinal bleeding, intracranial bleeding).
  5. Pregnant or lactating women. i. For female participants of or male participants with female partner of childbearing potential, who are not willing to practice highly effective during the trial and for at least 6 months after [177Lu] Lu-DOTA-STR-17126 administration ii. Sexually active males must use a condom during intercourse while taking the drug and for 4 months after stopping treatment and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid. Female partners of childbearing potential should use highly effective contraceptive methods during and up to 6 months after stopping treatment.
  6. Have any medical condition that impairs complete bladder emptying. Participants with permanent urinary indwelling catheter (IDC) or nephrostomy may be allowed to enrol on a case-by-case basis in discussion with Principal Investigator, if it is determined not to put the patient at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
  7. Major surgery, defined as any surgical procedure that involves general anaesthesia and a significant incision (i.e., larger than what is required for placement of a central venous access, percutaneous feeding tube, or ) within 30 days before study day 1 or anticipated surgery within the subsequent 43 days (6 weeks).
  8. Has an additional active requiring therapy within the past 2 years.
  9. History of another malignancy within 3 years before study enrolment. A subject with the following malignancies is allowed if considered cured or unlikely to recur within 3 years:

    i. Carcinoma of the skin without melanomatous features ii. Curatively treated cervical carcinoma in situ iii. Bladder tumours considered superficial such as non-invasive (T1a) and carcinoma in situ (T1s), thyroid papillary cancer with prior treatment

  10. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy within 30 days prior to trial enrolment.
  11. Psychiatric illness/social situations that would interfere with compliance with study requirements.
  12. Cannot undergo PET/CT scanning because of weight limits (350 lbs or 160 kg).
  13. Prior exposure to any other GRPR-targeting therapeutic agents.
  14. Prior treatment with any systemic anti-cancer therapy including chemotherapy, immunotherapy, biological therapy, radiation therapy, biologic, hormonal or herbal therapy, or any investigational therapy or investigational device, unless:

    i. Standard of care or maintenance therapy such as, luteinizing hormone-releasing hormone (LHRH) or gonadotropin releasing hormone (GnRH) for patients with prostate cancer; selective estrogen receptor modulators or aromatase inhibitors or GnRH inhibitors for breast cancer, ii. Within more than 30 days of chemotherapy, herbal therapies and monoclonal antibodies, iii. Within more than 5 half-lives for biologic/non-cytotoxic targeted agents, iv. Within more than 8 weeks prior radiation therapies External Beam Radiotherapy (EBRT) and/or Radioligand Therapy (RLT). Focal palliative radiotherapy given within 8 weeks prior to the low dose of [177Lu] Lu-DOTA-STR-17126 may be approved on a case-by-case basis, if it is determined not to put the participant at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome, v. For participants who received radiotherapy (EBRT and/or RLT) more than 8 weeks prior to the low dose of 177Lu-DOTA-STR-17126, efforts should be made to calculate the prior radiation absorbed dose to each critical organ such as the kidneys, liver, lungs, and bone marrow.

  15. Patients with a history of inflammatory disease which according to the investigator may interfere with correct evaluation of radioactive uptake, especially those affecting the thoraco-abdominal cavities (i.e., , granulomatous disease).
  16. Any clinically significant toxicity (with the exception of alopecia) related to prior anti-tumour therapy not resolved to Grade 1 or baseline.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Early Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu]Lu-DOTA-STR-17126

    The intervention involves administration of two radiopharmaceuticals under investigation: Part 1: \[68Ga\] Ga-DOTA-STR-17126 is used as a PET imaging tracer to identify tumour lesions with high expression of GRPR. Participants will receive a single intravenous bolus dose of 150+/-50MBq (50 micrograms) of DOTA-STR-17126 precursor. Part 2: Participants who have GRPR positive lesions identified by \[68Ga\] Ga-DOTA-STR-17126 PET imaging will receive a low Dose \[177Lu\] Lu-DOTA-STR-17126. Eligible participant(s) will receive 1.0+/-0.5GBq (50 microgram peptide) dose of \[177Lu\] Lu-DOTA-STR-17126, administered as a slow intravenous infusion. SPECT/CT scans will be performed to assess the biodistribution, dosimetry, and extrapolation of potential therapeutic dose potential of the radiopharmaceutical.

    Drug: [177Lu]Lu-DOTA-STR-17126 · Drug: [68Ga]Ga-DOTA-STR-17126

Interventions

  • DrugLutetium-177Studies of Lutetium-177Lutetium-177 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive a low dose of \[177Lu\]Lu-DOTA-STR-17126, dose activity: 1.0+/-0.5 GBq (50 micrograms peptide) of \[177Lu\]Lu-DOTA-STR-17126 precursor will be administered as a slow infusion.

  • DrugGallium-68Studies of Gallium-68Gallium-68 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive a single intravenous bolus dose of 150+/-50MBq (25 - 50 micrograms) of \[68Ga\]Ga-DOTA-STR-17126 precursor.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs), serious adverse events (SAEs), with abnormal laboratory parameters (hematology, blood chemistry, and urinalysis), abnormal Physical examinations findings

    1\. To evaluate adverse events (AEs) and serious adverse events (SAEs) by means of Common Toxicity Criteria Adverse Events (CTCAE version 5.0 Nov 2017); Assess occurrence and severity of AEs and SAEs; Monitor safety laboratory parameters (haematology, blood chemistry, and urinalysis) before, during and after IMP injections. The Common Terminology Criteria for Adverse Events (CTCAE) is a standardized, 1-5 severity grading system for classifying cancer treatment side effects (adverse events). Grades range from mild (1) to death (5). It is widely used in oncology to determine treatment safety, drug dosage modifications, and to document clinical trial toxicity

    Time frame: Day 43

Secondary outcomes

  1. Standardized Uptake Value (SUV) of [⁶⁸Ga]Ga-DOTA-STR-17126

    Calculation of Standardized Uptake Value (SUV) (max, mean, peak) \* between tumour and suitable reference organs (using liver parenchyma, lung parenchyma and mediastinal blood pool as reference regions) by PET/CT imaging, Higher numbers e.g., above 2.5 often highly suggestive of malignancy (cancerous growth. Lower numbers e.g., below 2.5 frequently indicate benign (non-cancerous) growths. SUVmax vs. SUVmean: A scan report will usually specify SUV\_max as the highest, most active single point in the tumor or SUV\_mean (the average activity across the entire tumor.

    Time frame: Day 2 post-dose

  2. PET/CT image quality of [⁶⁸Ga]Ga-DOTA-STR-17126

    Qualitative assessment of PET/CT image quality using a 5-point scale from excellent to poor image, with parameters such as intensity, sharpness, noise of tumour uptake related to reference regions.

    Time frame: Day 2 post-dose

  3. Tumour to Background Ratio (TBR) of [⁶⁸Ga]Ga-DOTA-STR-17126

    The ability to confirm preferential accumulation of \[68Ga\] Ga-DOTA-STR-17126 in target lesions and comparable detectability of tumour lesions by PET/CT, taking also into account the extent of uptake in non-target normal organs, and establish intra-participant image quality protocol. • Tumour to Background Ratio (TBR). High TBR: Indicates a "hot" or very active tumor that is easy to distinguish from the surrounding healthy tissue (e.g., a TBR of 3.0 or higher). Low TBR: Indicates that the tumor looks very similar to the surrounding background tissue, which can make it difficult to identify or measure accurately.

    Time frame: Day 2 post-dose

  4. Concentration of [68Ga]Ga-DOTA-STR-17126 and [177Lu]Lu-DOTA-STR-17126

    Calculate concentration of \[68Ga\]Ga-DOTA-STR-17126 and of \[177Lu\]Lu-DOTA-STR-17126 in blood by counting radioactivity in respective samples at specific time intervals (radio-PK)

    Time frame: Day 1 post-dose, Day 2, Day 4, Day 8

  5. Percentage of injected activity (%IA) in tumour and non-tumour organs

    Calculate retention pattern within body and blood pool by the percentage of injected activity (%IA) in tumour and non-tumour organs

    Time frame: Day 1 post-dose, Day 2, Day 4, Day 8

  6. Calculation of absorbed dose (AD, mGy/MBq)

    Calculation of absorbed dose (AD, mGy/MBq) and effective whole-body dose (ED, mSv/MBq) of \[68Ga\]Ga-DOTA-STR-17126 and \[177Lu\]Lu-DOTA-STR-17126 The dosimetry analysis will enable estimated radiation absorbed doses from the radioligand therapeutic drug candidate \[177Lu\]Lu-DOTA-STR-17126 in organs and tumour lesions per unit administered activity (Gy/GBq).

    Time frame: Day 1 post-dose

Other outcomes

  1. Number of tumour lesions within tumour tissue sample that are positive for GRPR expression based on immunohistochemistry (IHC)

    To calculate the number of tumour lesions within tumour tissue sample that are positive for GRPR expression based on immunohistochemistry (IHC) or quantitative polymerase chain reaction (qPCR), protein and RNA, respectively

    Time frame: Pre-dose

  2. Staining intensity (% of positive cells and intensity) in tumour tissue

    To compare staining intensity (% of positive cells and intensity) in tumour tissue samples to SUVmax uptake in un-matched PET imaging scans

    Time frame: Pre-dose

07

Study locations

1 of 1 sites recruiting
  • Icon Cancer Centre Hollywood
    Perth, Western Australia 6009, Australia
    Recruiting
    • ICC Hollywood Admin Team · Contactadmin.hollywood@icon.team · +61 8 6326 1130
    • Dr Nat P Lenzo, MD · Principal investigator
    • Dr Gaurav Ghosh, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Future use of research data Data collected during the study may be utilised in future research by the Principal Investigators, Sponsor and collaborating researchers to advance knowledge about cancer and its treatments. Proposals for access to trial data must be reviewed and approved by the PI. Participants in this study will be asked to grant advanced permission for the possible future sharing of the data collected in this study. Additional participant consent for use of the data will only be sought if it is a requirement of the HREC.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: 2029 for 12 months

Access criteria: Email the study's central contact, provide a reason for your request, subject to review by the PI and Sponsor Oversight committee. You may be required to enter into a data sharing agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2028, 24 months after the start.

Of 373 non-industry phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 77. This study's planned 24 months is below that.

Counting every sponsor, half of 763 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
May 27, 2026
StartActual
May 28, 2026
Primary completionEst.
May 30, 2028
CompletionEst.
May 31, 2029
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07608848
Lead sponsor
Integrated Haematology and Oncology Network
Responsible party
Sponsor
First posted
May 27, 2026
Start date
May 28, 2026
Primary completion
May 30, 2028 (estimated)
Completion
May 31, 2029 (estimated)
Last update
Jun 10, 2026

Study contacts

Amma P Owusu, RN BSc MN
Contact
research.iit@icon.team
+61498120411
Duncan Colyer, RN BN PGDip
Contact
research.iit@icon.team
Nat Lenzo, MD
principal investigator · Integrated Hematology Oncology Network (Icon Group)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lutetium-177 · Gallium-68

Start the discussion